文献速递药物相互作用治疗药物监测与药物基因组学

卡马西平导致转移性去势抵抗性前列腺癌患者阿比特龙暴露量临床相关下降

A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer.
PubMed 文献 · Br J Clin Pharmacol · 2018-02-21

一名65岁转移性去势抵抗性前列腺癌患者在接受阿比特龙醋酸酯和泼尼松龙治疗期间,因面部神经病变合用卡马西平,导致阿比特龙暴露量下降超过2倍(AUC和谷浓度)。停用卡马西平后阿比特龙暴露量恢复正常,未发现其他替代原因。机制为卡马西平诱导CYP3A及可能诱导SULT2A1。

要点

  • 卡马西平可诱导CYP3A和SULT2A1,使阿比特龙暴露量下降超过2倍。
  • 国家药物相互作用检查器不警告此相互作用,Lexicomp和Micromedex建议避免或增加给药频次至每日两次。
  • 应避免卡马西平与阿比特龙联用,无法避免时可用阿比特龙治疗药物监测指导治疗。

核心结论

  • 卡马西平与阿比特龙联用可导致阿比特龙暴露量临床相关下降超过2倍,应避免联用。

研究设计与样本

  • 病例报告:一名65岁转移性去势抵抗性前列腺癌患者,接受阿比特龙醋酸酯和泼尼松龙治疗,因面部神经病变合用卡马西平。

主要发现

  • 合用卡马西平后阿比特龙暴露量(AUC和谷浓度)下降超过2倍。
  • 停用卡马西平后阿比特龙暴露量恢复正常。
  • 未发现其他可解释阿比特龙暴露量下降的替代原因。

关键数值与推荐

  • 阿比特龙暴露量下降超过2倍(AUC和谷浓度)。
  • Lexicomp和Micromedex建议避免联用或增加阿比特龙给药频次至每日两次。
  • 国家药物相互作用检查器不警告此相互作用。

临床怎么用

  • 应避免卡马西平与阿比特龙联用以防暴露不足和治疗不充分。
  • 无法避免药物相互作用时,可用阿比特龙治疗药物监测指导治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ADVERSE EVENT: Decreased abiraterone exposure after introducing carbamazepine. DRUGS IMPLICATED: Abiraterone acetate and carbamazepine. THE PATIENT: A 65-year-old man with metastatic castration resistant prostate cancer, was treated with abiraterone acetate and prednisolone, and received concomitant carbamazepine for treatment of facial neuropathy. EVIDENCE THAT LINKS THE DRUG TO THE EVENT: The interaction was confirmed by a decrease in abiraterone exposure >2-fold (area-under-the-curve and trough levels). After discontinuation of carbamazepine therapy, the abiraterone exposure normalized. No alternative causes were found that explain the decrease in abiraterone exposure. MECHANISM: Induction of CYP3A and potentially phase I metabolism (SULT2A1) by carbamazepine. IMPLICATIONS FOR THERAPY: Clinicians and pharmacists should be aware of this clinically relevant interaction. The national drug-drug interaction checker does not warn for this interaction, whereas both the Lexicomp® and Micromedex® advice to avoid if possible or to increase the abiraterone dose frequency to twice daily. Carbamazepine should not be combined with abiraterone to avoid underexposure and suboptimal therapy. Therapeutic drug monitoring of abiraterone is useful to guide therapy when drug-drug interactions cannot be avoided.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Benoist GE, van der Doelen MJ, Ter Heine R, et al. A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. Br J Clin Pharmacol. 2018. PMID: 29384591. doi:10.1111/bcp.13532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。